Cholesterol levels in patients on any EVR regimen should however be closely monitored, since dyslipidemia, as a known side effect of mTOR inhibitors, increases the risk of cardiovascular diseases and complications, such as atherosclerosis and myocardial infarction (39). The gene discussed is MTOR; the disease is metabolic syndrome.